CommercialPrior AuthMedium impact
08.01.93e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease
Independence Blue Cross·Neurology, Geriatrics, Internal Medicine·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes coverage and medical necessity criteria for monoclonal antibodies directed against amyloid for Alzheimer Disease treatment, effective January 1, 2025. The billing team must implement prior authorization requirements and ensure claims comply with updated medical necessity guidelines for these specialty biologics.
Action Required
By January 1, 2025: Billing team must update system workflows to require prior authorization for all monoclonal antibody amyloid-directed treatments for Alzheimer Disease on commercial plans. Coordinate with providers to ensure medical necessity documentation (cognitive decline severity, amyloid positivity confirmation, patient age/comorbidity factors) is included with all claims. Add clinical documentation checklist to EMR templates for neurology/geriatrics departments. Update insurance verification process to flag Alzheimer Disease amyloid treatments for PA verification. Obtain and review the full policy text at the source URL to identify any specific HCPCS or J-codes for these biologics, as they are not specified in the notification summary. Claims submitted without required prior authorization and medical necessity documentation will be denied.